Clinical Trials Arena February 2, 2023
After their success in Covid-19, can mRNA vaccines breakthrough in influenza, herpes, and even cancer?
Following the success of messenger RNA (mRNA) vaccines in Covid-19, there has been a surge of investment in new trials. Recent positive clinical studies in melanoma and respiratory syncytial virus (RSV) have now shown that mRNA vaccines could prove effective beyond treating Covid-19, and the pharma world has taken note.
In 2023, four major trials in influenza, genital herpes, and melanoma will show just how far-reaching mRNA vaccine technology could be. These include Moderna’s mRNA-1010 and Pfizer’s modRNA vaccine in seasonal influenza, Roche/BioNTech’s RO7198457 in advanced melanoma, and BioNTech’s BNT-163 for lesions in genital herpes.
Although most early clinical research into mRNA vaccines...
Today's Sponsors
Today's Sponsor